COMPASS Pathways Company Description

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States.

It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa.

The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.

The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

COMPASS Pathways plc

Country	United Kingdom
Founded	2020
Industry	Biological Products, Except Diagnostic Substances
Employees	166
CEO	Kabir Nath

Contact Details

Address: 33 Broadwick Street London, W1F 0DQ United Kingdom
Website	compasspathways.com

Stock Details

Ticker Symbol	5Y6
Exchange	Frankfurt Stock Exchange
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
Kabir Nath	Chief Executive Officer
Teri Loxam	Chief Financial Officer
Stephen Schultz	Head of Investor Relations